[go: up one dir, main page]

WO2001067890A3 - Composition and method to treat weight gain and obesity attributable to psychotropic drugs - Google Patents

Composition and method to treat weight gain and obesity attributable to psychotropic drugs Download PDF

Info

Publication number
WO2001067890A3
WO2001067890A3 PCT/US2001/006637 US0106637W WO0167890A3 WO 2001067890 A3 WO2001067890 A3 WO 2001067890A3 US 0106637 W US0106637 W US 0106637W WO 0167890 A3 WO0167890 A3 WO 0167890A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
attributable
obesity
psychotropic drugs
weight gain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/006637
Other languages
French (fr)
Other versions
WO2001067890A2 (en
Inventor
Judith J Wurtman
Richard J Wurtman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Priority to AU2001243369A priority Critical patent/AU2001243369A1/en
Publication of WO2001067890A2 publication Critical patent/WO2001067890A2/en
Publication of WO2001067890A3 publication Critical patent/WO2001067890A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L9/00—Puddings; Cream substitutes; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

A composition and method of use for the prevention and/or treatment of weight problems attributed to the use of psychotropic drugs. The composition contains at least one form of carbohydrate and is substantially free of protein. In a preferred embodiment the composition is in the form of a snack food. Administration of the snack food results in an elevation of the subject's plasma Tp/Lnaa ratio, relative to the subject's pre-administration plasma Tp/Lnaa ratio. In alternative embodiments, the snack food either further contains tryptophan, 5-hydroxytryptophan, or melatonin, or is administered either after, concurrently, or before the administration of a second composition that contains either tryptophan, 5-hydroxytryptophan or melatonin.
PCT/US2001/006637 2000-03-14 2001-03-02 Composition and method to treat weight gain and obesity attributable to psychotropic drugs Ceased WO2001067890A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001243369A AU2001243369A1 (en) 2000-03-14 2001-03-02 Composition and method to treat weight gain and obesity attributable to psychotropic drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52505800A 2000-03-14 2000-03-14
US09/525,058 2000-03-14

Publications (2)

Publication Number Publication Date
WO2001067890A2 WO2001067890A2 (en) 2001-09-20
WO2001067890A3 true WO2001067890A3 (en) 2002-02-07

Family

ID=24091738

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006637 Ceased WO2001067890A2 (en) 2000-03-14 2001-03-02 Composition and method to treat weight gain and obesity attributable to psychotropic drugs

Country Status (2)

Country Link
AU (1) AU2001243369A1 (en)
WO (1) WO2001067890A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004271796A1 (en) * 2003-09-12 2005-03-24 Warner-Lambert Company Llc Combination comprising an alpha-2-delta ligand and an SSRI and/or SNRI for treatment of depression and anxiety disorders
WO2007016950A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing the risk of alcohol induced neurodegenerative disease
WO2007016949A1 (en) * 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Composition for reducing the risc of alcohol induced neuropathy
EP1909600B1 (en) 2005-07-29 2012-04-25 TIMA Foundation Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases
CN1299681C (en) * 2005-08-29 2007-02-14 陈彦方 Health caring formulation for treating insomnia
WO2008050344A2 (en) * 2006-10-25 2008-05-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment of hepatic encephalopathy and liver cirrhosis
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
CN113993522A (en) 2019-04-17 2022-01-28 指南针探路者有限公司 Method for treating anxiety disorders, headache disorders and eating disorders with siloxibin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0007691A1 (en) * 1978-07-31 1980-02-06 Massachusetts Institute Of Technology Compositions for use in decreasing appetite for calories as carbohydrates
US4497800A (en) * 1982-07-06 1985-02-05 Mead Johnson & Company Stable liquid diet composition
WO1996039868A1 (en) * 1995-06-07 1996-12-19 Massachusetts Institute Of Technology Composition and methods for losing weight

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0007691A1 (en) * 1978-07-31 1980-02-06 Massachusetts Institute Of Technology Compositions for use in decreasing appetite for calories as carbohydrates
US4497800A (en) * 1982-07-06 1985-02-05 Mead Johnson & Company Stable liquid diet composition
WO1996039868A1 (en) * 1995-06-07 1996-12-19 Massachusetts Institute Of Technology Composition and methods for losing weight

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NOBREGA J N ET AL: "EFFECTS OF CHRONIC AMITRIPTYLINE AND DESIPRAMINE ON FOOD INTAKE AND BODY WEIGHT IN RATS", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 27, no. 1, 1987, pages 105 - 112, XP001030528, ISSN: 0091-3057 *
RUSS M J ET AL: "L TRYPTOPHAN DOES NOT AFFECT FOOD INTAKE DURING RECOVERY FROM DEPRESSION", INTERNATIONAL JOURNAL OF EATING DISORDERS, vol. 10, no. 5, 1991, pages 539 - 546, XP001030530, ISSN: 0276-3478 *

Also Published As

Publication number Publication date
AU2001243369A1 (en) 2001-09-24
WO2001067890A2 (en) 2001-09-20

Similar Documents

Publication Publication Date Title
EP2044940A3 (en) Methods of treating patients suffering from movement disorders
MX339071B (en) Pregelatinized starch in a controlled release formulation.
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
EP0735863A1 (en) Accelerated release composition containing bromocriptine
AU684059B2 (en) Application of riluzole in the treatment of Parkinson's disease and Parkinsonian syndromes
DE69518767D1 (en) MEDICINAL PRODUCTS CONTAINING ONDASETRON
UA88270C2 (en) Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes
BG105534A (en) 5ht1 means and method for the treatment of migraine
WO1999045920A3 (en) The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
WO2001067890A3 (en) Composition and method to treat weight gain and obesity attributable to psychotropic drugs
WO2002089778A3 (en) Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
WO1999044608A8 (en) New use
JP2004537500A5 (en)
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
WO2004050025A3 (en) Combination of ibuprofen and oxycodone for acute pain relief
AU6153400A (en) Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients
HK1046092A1 (en) Fat-binding polymers, optionally combined with lipase inhibitors
NO984572D0 (en) Use of 2,5-dihydroxybenzenesulfone derivatives for the manufacture of drugs intended for normalization of endothelial function, for the treatment of sexual dysfunction and vascular complications in diabetes, as well as vascular disorders of
García–Tsao Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: a caution
SE0102887D0 (en) New formulation
EP1051995A3 (en) 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine
Sommer et al. A conservative treatment option of curing venous leakage in impotent men
EP1064948A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
EP1051993A3 (en) 5HT1 receptor agonists and either a COX-2 inhibitor or NSAID for the treatment of migraine
EP1064967A3 (en) 5HT1 receptor agonists, caffeine and either a COX-2 inhibitor or NSAID for the treatment of migraine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP